DASH prediction score: Difference between revisions

Jump to navigation Jump to search
 
(8 intermediate revisions by 2 users not shown)
Line 9: Line 9:


==DASH Prediction Score==
==DASH Prediction Score==
[Name of the Score] was invented by (Author) et al in (year), and has been externally validated in (other populations/subsequent studies).(add references)
* DASH Prediction Score was invented by A. Tosetto et al in 2012<ref name="TosettoIorio2012">{{cite journal|last1=Tosetto|first1=A.|last2=Iorio|first2=A.|last3=Marcucci|first3=M.|last4=Baglin|first4=T.|last5=Cushman|first5=M.|last6=Eichinger|first6=S.|last7=Palareti|first7=G.|last8=Poli|first8=D.|last9=Tait|first9=R. C.|last10=Douketis|first10=J.|title=Predicting disease recurrence in patients with previous unprovoked venous thromboembolism: a proposed prediction score (DASH)|journal=Journal of Thrombosis and Haemostasis|volume=10|issue=6|year=2012|pages=1019–1025|issn=15387933|doi=10.1111/j.1538-7836.2012.04735.x}}</ref>, and has been externally validated in subsequent study in 2017<ref name="TosettoTesta2017">{{cite journal|last1=Tosetto|first1=A.|last2=Testa|first2=S.|last3=Martinelli|first3=I.|last4=Poli|first4=D.|last5=Cosmi|first5=B.|last6=Lodigiani|first6=C.|last7=Ageno|first7=W.|last8=De Stefano|first8=V.|last9=Falanga|first9=A.|last10=Nichele|first10=I.|last11=Paoletti|first11=O.|last12=Bucciarelli|first12=P.|last13=Antonucci|first13=E.|last14=Legnani|first14=C.|last15=Banfi|first15=E.|last16=Dentali|first16=F.|last17=Bartolomei|first17=F.|last18=Barcella|first18=L.|last19=Palareti|first19=G.|title=External validation of the DASH prediction rule: a retrospective cohort study|journal=Journal of Thrombosis and Haemostasis|volume=15|issue=10|year=2017|pages=1963–1970|issn=15387933|doi=10.1111/jth.13781}}</ref> particularly in young adults.


[Name of the Score] is a (risk assessment tool/risk stratification scheme) designed to assess the (30-day/5-year) risk of (bleeding/ischemia/other end point) associated with (antiplatelet/antithrombotic/other treatment) among patients with (coronary heart disease/heart failure/other condition).
* DASH Prediction Score is a clinical prediction rule devised to assess the recurrence in patients with previous unprovoked  venous thromboembolism especially in people aged <65 years.This helps decide whether anticoagulation be continued indefinitely or stopped after at least 3 months of anticoagulation.<ref name="pmid26316770">{{cite journal |vauthors=Fahrni J, Husmann M, Gretener SB, Keo HH |title=Assessing the risk of recurrent venous thromboembolism--a practical approach |journal=Vasc Health Risk Manag |volume=11 |issue= |pages=451–9 |date=2015 |pmid=26316770 |doi=10.2147/VHRM.S83718 |url=}}</ref>
 
[Name of the Score] is a (clinical prediction rule) devised to assess the severity of (acute pancreatitis/other disease) among (hospitalized patients/healthy individuals/other population) in the (outpatient/inpatient/surgical/medical/emergency room) setting.
 
[Name of the Score] is a (prediction model) developed to estimate the (mortality/bleeding rate/pre-test probability) of (acute pulmonary embolism/other disease) among (hospitalized patients/healthy individuals/other population).
 
[Name of the Score] is a (decision tool) designed to assist the decision-making pertaining to the (risk/benefit) of (antiplatelet/antithrombotic/other treatment) for (acute coronary syndrome/other conditions) among (hospitalized patients/healthy individuals/other population).


==DASH Prediction Score Calculator==
==DASH Prediction Score Calculator==
Line 26: Line 20:
==Interpretation==
==Interpretation==
*  
*  
{| class="wikitable"
{|
|+
|+
! rowspan="2" |Score
! rowspan="2" style="background:#4479BA; color: #FFFFFF;" align="center" + |Score
! rowspan="2" |Annualized recurrence rate
! rowspan="2" style="background:#4479BA; color: #FFFFFF;" align="center" + |Annualized recurrence  
! colspan="3" |Cumulative recurrence rate
rate (%)
! colspan="3" style="background:#4479BA; color: #FFFFFF;" align="center" + |Cumulative recurrence rate(%)
|-
! style="background:#4479BA; color: #FFFFFF;" align="center" + |1 year
! style="background:#4479BA; color: #FFFFFF;" align="center" + |2 year
! style="background:#4479BA; color: #FFFFFF;" align="center" + |5 year
|-
|-
!1 year
| style="background:#DCDCDC;" align="center" + | - 2
!2 year
| style="background:#F5F5F5;" align="center" + |1.8
!5 year
| style="background:#F5F5F5;" align="center" + |2.4
| style="background:#F5F5F5;" align="center" + |5.2
| style="background:#F5F5F5;" align="center" + |5.2
|-
|-
| - 2
| style="background:#DCDCDC;" align="center" + | - 1
|
| style="background:#F5F5F5;" align="center" + |1.0
|
| style="background:#F5F5F5;" align="center" + |1.9
|
| style="background:#F5F5F5;" align="center" + |1.9
|
| style="background:#F5F5F5;" align="center" + |5.7
|-
|-
| - 1
| style="background:#DCDCDC;" align="center" + |0
|
| style="background:#F5F5F5;" align="center" + |2.4
|
| style="background:#F5F5F5;" align="center" + |4.2
|
| style="background:#F5F5F5;" align="center" + |5.4
|
| style="background:#F5F5F5;" align="center" + |9.5
|-
|-
|
| style="background:#DCDCDC;" align="center" + |1
|
| style="background:#F5F5F5;" align="center" + |3.9
|
| style="background:#F5F5F5;" align="center" + |5.1
|
| style="background:#F5F5F5;" align="center" + |8.7
|
| style="background:#F5F5F5;" align="center" + |15.9
|-
|-
|
| style="background:#DCDCDC;" align="center" + |2
|
| style="background:#F5F5F5;" align="center" + |6.3
|
| style="background:#F5F5F5;" align="center" + |8.4
|
| style="background:#F5F5F5;" align="center" + |12.8
|
| style="background:#F5F5F5;" align="center" + |25.3
|-
|-
|
| style="background:#DCDCDC;" align="center" + |3
|
| style="background:#F5F5F5;" align="center" + |10.8
|
| style="background:#F5F5F5;" align="center" + |14.6
|
| style="background:#F5F5F5;" align="center" + |20.5
|
| style="background:#F5F5F5;" align="center" + |40.9
|-
|-
|
| style="background:#DCDCDC;" align="center" + |4
|
| style="background:#F5F5F5;" align="center" + |19.9
|
| style="background:#F5F5F5;" align="center" + |21.9
|
| style="background:#F5F5F5;" align="center" + |33.6
|
| style="background:#F5F5F5;" align="center" + |61.3
|}
|}
* Score – 2: annualized recurrence rate 1.8%
* Score – 2: annualized recurrence rate 1.8%

Latest revision as of 13:49, 25 October 2019


Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: (insert your name here)

Synonyms and keywords: (add synonyms and create redirects)

Overview

[Name of the Score] is a (± validated) risk assessment tool designed to assess the (30-day/10-year/other timeframe) risk of (bleeding/ischemia/other end point) associated with (antiplatelet/antithrombotic/other treatment) among patients with (coronary heart disease/heart failure/other condition).

DASH Prediction Score

  • DASH Prediction Score was invented by A. Tosetto et al in 2012[1], and has been externally validated in subsequent study in 2017[2] particularly in young adults.
  • DASH Prediction Score is a clinical prediction rule devised to assess the recurrence in patients with previous unprovoked venous thromboembolism especially in people aged <65 years.This helps decide whether anticoagulation be continued indefinitely or stopped after at least 3 months of anticoagulation.[3]

DASH Prediction Score Calculator

Shown below is the calculator for DASH prediction score (check all the boxes that apply):

DASH Prediction Score Calculator
Variable Score
Elevated D-dimer levels 2
Age ≤ 50 years 1
Sex-male 1
Women with hormone-associated VTE -2
DASH Prediction Score:
Interpretation:

Interpretation

Score Annualized recurrence

rate (%)

Cumulative recurrence rate(%)
1 year 2 year 5 year
- 2 1.8 2.4 5.2 5.2
- 1 1.0 1.9 1.9 5.7
0 2.4 4.2 5.4 9.5
1 3.9 5.1 8.7 15.9
2 6.3 8.4 12.8 25.3
3 10.8 14.6 20.5 40.9
4 19.9 21.9 33.6 61.3
  • Score – 2: annualized recurrence rate 1.8%
  • Score 2–3: intermediate-risk (1 to 5% mortality); consider treatment or hospitalization.
  • Score ≥ 4: high-risk (> 5% mortality); treatment/hospitalization is warranted.

See also

  • (Relevant score 1)
  • (Relevant score 2)
  • (Relevant score 3)

References

  1. Tosetto, A.; Iorio, A.; Marcucci, M.; Baglin, T.; Cushman, M.; Eichinger, S.; Palareti, G.; Poli, D.; Tait, R. C.; Douketis, J. (2012). "Predicting disease recurrence in patients with previous unprovoked venous thromboembolism: a proposed prediction score (DASH)". Journal of Thrombosis and Haemostasis. 10 (6): 1019–1025. doi:10.1111/j.1538-7836.2012.04735.x. ISSN 1538-7933.
  2. Tosetto, A.; Testa, S.; Martinelli, I.; Poli, D.; Cosmi, B.; Lodigiani, C.; Ageno, W.; De Stefano, V.; Falanga, A.; Nichele, I.; Paoletti, O.; Bucciarelli, P.; Antonucci, E.; Legnani, C.; Banfi, E.; Dentali, F.; Bartolomei, F.; Barcella, L.; Palareti, G. (2017). "External validation of the DASH prediction rule: a retrospective cohort study". Journal of Thrombosis and Haemostasis. 15 (10): 1963–1970. doi:10.1111/jth.13781. ISSN 1538-7933.
  3. Fahrni J, Husmann M, Gretener SB, Keo HH (2015). "Assessing the risk of recurrent venous thromboembolism--a practical approach". Vasc Health Risk Manag. 11: 451–9. doi:10.2147/VHRM.S83718. PMID 26316770.